Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Two additional U.S. sleep medicine groups have agreed to take on Oventus’ O₂Vent sleep technology to treat obstructive sleep apnoea
  • Delaware Sleep Disorder Centres and Reliable Respiratory will use O₂Vent across 10 facilities
  • Oventus is hoping to expand more into the U.S., Canada and Australia after coming off a successful $9.3 million capital raise

An additional two United States sleep medicine groups have agreed to take on Oventus’ O₂Vent sleep technology to treat obstructive sleep apnoea (OSA) at their facilities.

Delaware Sleep Disorder Centres and Reliable Respiratory will roll-out Oventus’ O₂Vent sleep treatment platform and lab in lab business models across a total of 10 facilities.

Under the agreement Oventus will be the exclusive supplier of dental sleep services to treat OSA.

The agreements will be officially launched as soon as the O₂Vent Optima oral device has received regulatory clearance from the U.S. Food and Drug Administration.

This is expected to be received sometime in the second half of the 2019 calendar year.

“It is very encouraging to see strong continued interest from U.S. sleep centres who are keen to deliver Oventus’ sleep treatment platform to patients,” Oventus CEO Dr Chris Hart said.

Today’s news follows earlier agreements with companies in both the U.S. and Canada. Additionally a number of contracts are being negotiated in Canada to sell Oventus’ Optima and oral PEEP valve ExVent devices.

According to Oventus its OSA treatment technology is equivalent to the current care standard of the continuous positive airway pressure (CPAP) machine.

While this is effective in treating OSA, patients must wear a mask while sleeping that blows air into the throat.

This can be uncomfortable and awkward with up to 60 per cent of suffers quitting in the first year of using.

Oventus’ O₂Vent technology has the design of a mouthguard but it enables unobstructed air to flow through the device and into the back of the throat. This bypasses common sites of obstruction such as the nose, tongue and soft palate.

Four clinical studies have proven this technology to be effective with more than 170 patients benefiting from it.

Oventus has also increased its cash reserves by $9.3 million via a recent capital raise and entitlement offer with Dr Hart hoping some of the funds will be used to expand Oventus’ customer base.

“With the support of our recent capital raising, we are in a strong positing to deliver on more agreement like these across our key markets of the U.S., Canada and Australia,” he said.

OVN by the numbers
More From The Market Herald
Chimeric Therapeutics (ASX:CHM) - CEO and MD, Jennifer Chow

" Chimeric Therapeutics (ASX:CHM) completes first milestone on path to clinical trial

Chimeric Therapeutics (CHM) has manufactured its phase one plasmids for its clinical trial.
Rhythm Biosciences (ASX:RHY) - Chairman, Otto Buttula

" Rhythm Biosciences (ASX:RHY) nears ColoSTAT commercialisation

Cancer diagnostics technology company Rhythm Biosciences (RHY) has updated the market regarding the commercialisation of ColoSTAT.

" Epsilon (ASX:EPN) signs manufacturing agreement for Jamaican cannabis

Epsilon Healthcare (EPN) has signed a long term manufacturing agreement for Cannim’s Jamaican cannabis products.
Suda Pharmaceuticals (ASX:SUD) - CEO and MD, Michael Baker

" SUDA Pharmaceuticals (ASX:SUD) has insomnia treatment approved in Chile

SUDA Pharmaceuticals (SUD) has had its lead product, ZolpiMist, for short-term insomnia in adults, approved by the Chile Ministry of Health.